Almost 140,000 people die with a drug-resistant bacterial infection in Brazil every year due in large part to shortcomings in access, stewardship, and innovation for antimicrobials. Brazil’s existing Productive Development Partnerships system could be modified to reduce incentives for overselling an...
Antimicrobial resistance (AMR) poses a threat to global health security worldwide, and India carries one of the largest burdens of drug-resistant pathogens. The widespread misuse and overuse of antimicrobials is a major cause of the emergence and spread of resistant microorganisms. This study assess...
With global challenges high on the international agenda and financing set to increase in the coming years, a big push on evidence, backed by dedicated resources, is essential. This note makes the case for a reinvigorated evidence agenda to boost the impact of financing for development and global pub...
Rigorous, explicit, evidence-informed priority-setting (EIPS) in healthcare is an essential instrument for achieving value for money. Growing pressures on healthcare budgets, combined with the post-COVID-19 fiscal crises and plateauing development assistance for health, make institutionalising EIPS ...
HTAIn has shown a good realised return on investment of 9:1. To further increase the return on investment, India can strategically scale up HTAIn and carry out careful selection of which topics to carry out HTAs on.
The policy discussions about PPR are noteworthy. But the global public sector is underinvesting in pandemic response. This creates the illusion of safety without the finance or planning in place to provide it. We cannot delay planning for response financing when the next pandemic hits, by which time...
This CGD note summarizes the implications of the macroeconomic context and broader financing outlook for domestic and external health spending and proposes a “menu” of policy options to keep health spending on track and blunt negative impacts on health systems and population health around the world.